Zhu Chen Selected Research

Acute Promyelocytic Leukemia

5/2021	Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia.
1/2021	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
1/2021	A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
1/2020	RIG-I regulates myeloid differentiation by promoting TRIM25-mediated ISGylation.
4/2018	Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
1/2018	Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment.
11/2017	Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.
1/2016	The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
12/2015	Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.
6/2015	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhu Chen Research Topics

Disease

51	Neoplasms (Cancer) 01/2022 - 09/2002
43	Acute Promyelocytic Leukemia 05/2021 - 06/2000
41	Leukemia 01/2021 - 02/2002
17	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2021 - 05/2005
12	COVID-19 01/2021 - 01/2020
11	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2012 - 12/2004
10	Hematologic Neoplasms (Hematological Malignancy) 12/2021 - 05/2005
9	Infections 12/2021 - 09/2003
9	Inflammation (Inflammations) 10/2021 - 05/2015
7	Thrombosis (Thrombus) 01/2017 - 01/2013
7	Lymphoma (Lymphomas) 10/2013 - 04/2003
6	Rheumatoid Arthritis 07/2022 - 03/2013
6	Hemorrhage 12/2021 - 09/2014
5	Atherosclerosis 09/2012 - 06/2010
4	Obesity 05/2022 - 01/2016
4	Hepatocellular Carcinoma (Hepatoma) 05/2021 - 05/2016
4	Genetic Translocation (Chromosomal Translocation) 01/2019 - 11/2002
4	Hypoxia (Hypoxemia) 11/2016 - 01/2006
3	Arthritis (Polyarthritis) 01/2021 - 11/2016
3	Disease Progression 11/2020 - 01/2005
3	Carcinogenesis 10/2020 - 02/2009
3	Virus Diseases (Viral Diseases) 01/2020 - 07/2008
3	Weight Gain 02/2019 - 02/2014
3	Graves Disease (Basedow Disease) 10/2018 - 08/2011
3	Carcinoma (Carcinomatosis) 01/2018 - 03/2009
3	Premature Birth (Birth, Premature) 10/2016 - 02/2014
3	Dyslipidemias (Dyslipidemia) 09/2012 - 06/2011
3	Myeloproliferative Disorders (Myeloproliferative Disorder) 03/2012 - 02/2008
2	Pancreatitis 02/2022 - 01/2021
2	Adenocarcinoma of Lung 01/2022 - 01/2021
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2021 - 09/2007
2	Hemophilia B (Haemophilia B) 10/2021 - 06/2015
2	Experimental Arthritis 01/2021 - 07/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2018
2	Dysbiosis 01/2021 - 01/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 01/2018
2	Substance-Related Disorders (Drug Abuse) 01/2021 - 01/2020
2	Hemophilia A (Haemophilia) 01/2021 - 02/2008
2	Morphine Dependence 01/2021 - 01/2020
2	Pneumonia (Pneumonitis) 11/2020 - 11/2020

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2004
26	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 02/2002
19	Pharmaceutical PreparationsIBA 09/2021 - 12/2003
18	Arsenic Trioxide (Trisenox)FDA Link 01/2021 - 02/2002
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2007
11	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 12/2004
11	ArsenicIBA 01/2018 - 01/2005
9	Imatinib Mesylate (Gleevec)FDA Link 02/2012 - 12/2004
8	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 02/2010 - 06/2000
7	AntigensIBA 01/2022 - 01/2006
7	Transcription Factors (Transcription Factor)IBA 10/2021 - 01/2007
7	EnzymesIBA 09/2021 - 04/2013
7	Therapeutic UsesIBA 12/2020 - 05/2005
7	Glucose (Dextrose)FDA LinkGeneric 11/2020 - 03/2014
7	Biological ProductsIBA 01/2019 - 12/2003
6	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2018
6	CytokinesIBA 01/2021 - 02/2014
6	Aligeron (AS 2)IBA 02/2005 - 11/2002
5	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 03/2011
5	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2021 - 10/2007
5	MethyltransferasesIBA 01/2020 - 02/2010
5	Lysine (L-Lysine)FDA Link 01/2020 - 02/2010
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019 - 01/2005
5	Tyrosine Kinase InhibitorsIBA 02/2012 - 02/2006
5	Retinoic Acid Receptor alphaIBA 02/2010 - 02/2002
4	CholesterolIBA 01/2021 - 06/2010
4	Messenger RNA (mRNA)IBA 01/2021 - 09/2008
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 09/2003
4	Phosphotransferases (Kinase)IBA 01/2018 - 05/2005
4	Small Interfering RNA (siRNA)IBA 06/2015 - 09/2008
4	Arsenicals (Arsenic Compounds)IBA 04/2012 - 09/2002
3	Competitive Endogenous RNAIBA 01/2022 - 01/2018
3	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2011
3	Long Noncoding RNAIBA 05/2021 - 01/2018
3	AcidsIBA 05/2021 - 02/2012
3	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2020
3	Histones (Histone)IBA 01/2020 - 02/2010
3	Histone Deacetylase InhibitorsIBA 01/2019 - 12/2007
3	GlucosidesIBA 10/2016 - 03/2013
3	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2012 - 12/2010
3	ApolipoproteinsIBA 01/2012 - 06/2011
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2008 - 01/2007
2	Anti-Citrullinated Protein AntibodiesIBA 07/2022 - 01/2021
2	Insulin (Novolin)FDA Link 05/2022 - 02/2014
2	Triglycerides (Triacylglycerol)IBA 02/2022 - 06/2010
2	Chimeric Antigen ReceptorsIBA 12/2021 - 01/2019
2	Blood Coagulation Factors (Coagulation Factor)IBA 10/2021 - 06/2015
2	Virulence Factors (Pathogenicity Factors)IBA 09/2021 - 09/2003
2	RetinoidsIBA 05/2021 - 12/2005
2	NitrogenIBA 01/2021 - 10/2016
2	methylglyoxal bis(3-aminopropylamidinohydrazone)IBA 01/2021 - 01/2020
2	LipopolysaccharidesIBA 01/2021 - 05/2017
2	Nucleic AcidsIBA 12/2020 - 01/2020
2	C-Reactive ProteinIBA 11/2020 - 11/2020
2	fibrin fragment D (D-dimer)IBA 11/2020 - 08/2012

Therapy/Procedure

38	Therapeutics 01/2022 - 05/2002
9	Drug Therapy (Chemotherapy) 12/2021 - 04/2003
3	Anesthesia 04/2019 - 06/2018
2	Immunotherapy 12/2021 - 11/2020
2	Transplantation 01/2021 - 08/2015